Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR | P30613 | 14/20 | 0.64 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.48 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.48 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.48 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.48 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.48 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.48 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.48 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21976119 | 0.79 | PKLR (0.68) | PKLRAVPR1ACYP46A1 | |
| SCHEMBL16084066 | 0.79 | PKLR (1.00) | PKLR | |
| SCHEMBL16049701 | 0.78 | AVPR1A (0.58) | PKLRAVPR1ACYP46A1CHRM2CHRM3 | |
| SCHEMBL21977205 | 0.78 | PKLR (0.63) | PKLRAVPR1A | |
| SCHEMBL21976822 | 0.78 | PKLR (0.60) | PKLRAVPR1APRKAB2PRKAG1PRKAA2 | |
| SCHEMBL16083871 | 0.78 | PKLR (0.82) | PKLR | |
| SCHEMBL16083860 | 0.78 | PKLR (0.82) | PKLR | |
| SCHEMBL21976577 | 0.76 | PKLR (0.68) | PKLRAVPR1A | |
| SCHEMBL16084080 | 0.76 | PKLR (1.00) | PKLR | |
| SCHEMBL16084069 | 0.76 | PKLR (1.00) | PKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365545-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2016-06-14 | — | — | US | disclosed |
| US-9108921-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC (US) | 2015-08-18 | — | — | US | disclosed |
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288081-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PC, PDK2 | PKLR 14/4885AVPR1A 4191/4885TYK2 2254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.